Innovative Treatment for CML:

Tasigna (nilotinib) is a highly effective targeted therapy used primarily to treat Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML). As a tyrosine kinase inhibitor, Tasigna works by selectively blocking the proteins that promote the growth of cancer cells, specifically targeting and inhibiting the BCR-ABL kinase that drives most cases of CML. This precision therapy helps patients achieve faster and deeper remissions, contributing to a significant extension of disease-free periods.

Optimized for Patient Response:

Tasigna offers a robust treatment solution with dosing schedules that can be adjusted based on patient response and tolerance. This flexibility allows for personalized treatment plans that maximize efficacy while minimizing potential side effects, ensuring that each patient receives the most effective care tailored to their specific condition.

Supporting Long-term Health Outcomes:

Continued use of Tasigna has shown to sustain low levels of disease activity over extended periods. Patients treated with Tasigna have demonstrated superior long-term health outcomes compared to older treatments, with many achieving what is known as a 'deep molecular response,' which is associated with better overall survival rates. Tasigna not only treats CML effectively but also contributes to a significantly improved quality of life.